Zoek een klinische studie of trial
Andere zoekoptie(s)
24 Resultaat/Resultaten
Aanwerving proef
= 
; Lopend onderzoek
= 
; Gefinancierd door een IRDiRC-lid = 
; Member of a ERN = 
Nationale klinische studie(s)
BELGIË
VLAAMS BRABANT
LEUVEN
MyCIDPchoice: Een multicenter, gerandomiseerd, subjectblind, onderzoekerblind, placebogecontroleerd, parallelle-groepsstudie ter evaluatie van de werkzaamheid, veiligheid en verdraagbaarheid van Rozanolixizumab bij personen met chronische inflammatoire demyeliniserende polyradiculoneuropathie (CIDP) - BE
UZ Leuven - Campus Gasthuisberg
Dienst neurologie/ Department of Neurology
DUITSLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Phase III) -DE-
Institution: Information not provided - DE
FRANKRIJK
ILE-DE-FRANCE
CRÉTEIL
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study (Phase I-II)
CHU Henri Mondor
Service de neurologie
FRANKRIJK
ILE-DE-FRANCE
PARIS
MYCOPID : Does the Mycophenolate Improve the Ability of Weaning Patients Off the Treatment in Chronic Inflammatory Demyelinating Polyradiculopathy (CIDP) (Phase III)
APHP.Sorbonne Université, Hôpital de la Pitié-Salpêtrière
Explorations fonctionnelles neurologie
FRANKRIJK
NOUVELLE AQUITAINE
BORDEAUX
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Phase III) - FR
CHU - Hôpitaux de Bordeaux
Direction de la Recherche Clinique et de l'Innovation (DRCI) - Hôpitaux de Bordeaux
ITALIË
LOMBARDIA
ROZZANO
PRISM 2 - International, multicentre, efficacy and safety study of I10E in the maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: extension of PRISM study I10E-1302 (phase III) - IT
IRCCS Istituto Clinico Humanitas
Servizio di Diagnosi e Cura delle Polineuropatie
ITALIË
LOMBARDIA
ROZZANO
An international, multicentre, efficacy and safety study of I10E in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy (phase III) - IT
IRCCS Istituto Clinico Humanitas
Servizio di Diagnosi e Cura delle Polineuropatie
NEDERLAND
Noord-Holland
AMSTERDAM
OPTIC trial: Intraveneus immunoglobuline en intraveneus methylprednisolon als optimale inductie behandeling in CIDP (Fase III) - NL
Amsterdam UMC, locatie AMC
Afdeling Neurologie
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) - AT
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) -GB
Institution: Information not provided - AT
SPANJE
Cataluña
BARCELONA
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Phase III) - ES
Hospital Universitari Vall d'Hebron
Servicio de Neurología
SPANJE
Cataluña
BARCELONA
MyCIDPchoice: A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) - ES
Hospital Universitari Vall d'Hebron
Servicio de Neurología
SPANJE
Cataluña
BARCELONA
MyCIDPchoice: A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Neurología
SPANJE
Comunidad Valenciana
VALENCIA
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) - ES
Hospital Universitario y Politécnico La Fe
Servicio de Neurología
SPANJE
Comunidad Valenciana
VALENCIA
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Phase III) - ES
Hospital Universitario y Politécnico La Fe
Servicio de Neurología
SPANJE
Galicia
SANTIAGO DE COMPOSTELA
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Phase III) - ES
Hospital Clínico Universitario de Santiago
Servicio de Neurología
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
ADHERE: A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - ES
Institution: Information not provided - ES
SPANJE
Madrid
MADRID
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Phase III) - ES
Hospital Universitario La Paz
Servicio de Neurología
VERENIGD KONINKRIJK
Greater London
LONDON
OPTIC trial: Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP-GB
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)
VERENIGD KONINKRIJK
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Phase III) - UK
Institution: Information not provided - UK
ZWITSERLAND
Suisse Romande
ADDRESS: NOT PROVIDED - CH
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (Phase III) - CH
Institution: Information not provided - CH
Multinationale klinische studie(s)
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Institution: Information not provided - AT
OOSTENRIJK
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Institution: Information not provided - AT
USA
North Carolina
RALEIGH